Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma

NCT00431912 is registered in ClinicalTrials.gov with Valerio Therapeutics as lead sponsor.

NCT NCT00431912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00431912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma
Lead sponsor
Valerio Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2007
Completion date
September 30, 2011
Enrollment
25 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous t-cell lymphoma